Background: Glycohemoglobin (gHb), measured as hemoglobin (Hb) A 1c or as total gHb, provides a common means for assessing long-term glycemic control in individuals with diabetes mellitus. Genetic variants and chemically modified derivatives of Hb can profoundly affect the accuracy of these measurements, although effects vary considerably among commercially available methods. The prevalence of genetic variants such as HbS, HbC, and HbE, and chemically modified derivatives such as carbamyl-Hb among patient populations undergoing testing is not insignificant. Clinical laboratories and sites responsible for point-of-care testing of gHb need to be aware of the interferences produced in assays by these Hbs. Approach: We conducted a review of the literature describing the effects of variant Hbs on gHb assay methods commonly used in clinical laboratories. Content: This review summarizes the documented effects of both common and uncommon Hb variants and derivatives on the measurement of gHb. Where known, we discuss mechanisms of interference on specific assays and methodologies. We specifically address effects of commonly encountered Hbs, such as carbamyl-Hb, HbS, HbC, HbE, and HbF, on assays that use cationexchange chromatography, immunoassays, or boronate affinity methods for measuring gHb. Summary: A variety of patient-and laboratory-related factors can adversely affect the measurement of gHb in patients harboring Hb variants or derivatives. Identification of the variant or derivative Hb before or during testing may allow accurate measurement of gHb by the selection of a method unaffected by the given variant or derivative. However, laboratories should make avail-
gHb can be affected by chemical modifications of Hb, which may be chronically present in diabetic patients. These modifications may mimic gHb physically and chemically, leading to inaccurate determinations of gHb, particularly when separation methods based on charge differences are used. Carbamylated Hb, which is increased in uremic patients, represents the most frequently encountered derivative. High concentrations of acetylated Hb occur with uncommon mutations at the NH 2 terminus of the ␤-globin chain that enhance formation of acetyl-Hb in vivo. Although in vitro exposure of normal Hb to aspirin has been shown to produce acetylated Hb, no effects from in vivo exposure have been detected in patients chronically taking 1 g or less of aspirin a day (8 ) .
Many hemoglobinopathies, including sickle cell disease, homozygous HbC disease, HbSC disease, and ␤-thalassemia, frequently show increased amounts of minor Hb species, i.e., HbA 2 and HbF, which interfere with some gHb methods. In addition, pathologic conditions affecting red cell half-life, including hemolysis (9 ) , hemorrhage (9 ) , iron deficiency anemia (10, 11 ) , or red cell transfusion (12 ) affect gHb values.
gHbs
In healthy adults, Hb consists of ϳ97% HbA, 2.5% HbA 2 , and 0.5% HbF (13 ) . Fractionation of HbA by chromatography identifies several minor peaks referred to as HbA 1 , or fast Hbs, which include the glycated forms HbA 1a , HbA 1b , and HbA 1c (13 ) . These fast Hbs form as the result of a two-step reaction. In the first step, a reversible reaction between the free aldehyde group of glucose or other sugars and nonprotonated free amino groups on the Hb molecule forms a Schiff base. This reversible reaction is followed by an irreversible, nonenzymatic Amadori rearrangement that produces gHb (13 ) . The glycation alters the structure of the Hb molecule and decreases its net positive charge. Many forms of testing use one or both differences to separate gHb from nonglycated Hbs.
The N-terminal valine of the ␤ chain provides the most common site of glycation within the Hb tetramer, accounting for 80% of HbA 1 (13 ) . The IFCC defines HbA 1c as Hb that is irreversibly glycated at one or both Nterminal valines of the ␤ chains. The remaining gHbs have glucose, glucose-6-phosphate, fructose-1,6-diphosphate, or pyruvic acid bound to 1 of 44 additional sites occurring at ⑀-amino groups of lysine residues or at the NH 2 terminus of the ␣ chain (13 ) . Although all commercially available methods include HbA 1c in gHb measurements, they vary in their ability to detect non-A 1c gHb.
Current clinical recommendations of the American Diabetes Association suggest that gHb be maintained at 7%, consistent with a decreased risk for developing longterm complications from diabetes mellitus. A reevaluation of the treatment regimen should be undertaken in patients with repeated gHb values Ͼ8% (1 ) .
In a healthy individual, gHb readings reflect the degree of glycemic control over the preceding 2-3 months, reflecting the average circulating life span of 120 days for red blood cells (1 ) . Pathophysiological conditions affecting red cell turnover, such as sickle cell disease and HbCC and HbSC disease, thus limit the utility of gHb testing in assessing long-term glycemic control. Alternative tests, such as measurement of glycated serum proteins (GSPs) and glycated serum albumin (GSA), should be performed when the interpretation of gHb is confounded by variables affecting red cell turnover or when Hb variants affect the ability of the Hb molecule to be glycated. However, clinicians should be aware of two important points concerning the use of GSPs or GSA as measures of long-term glycemic control: (a) these tests assess the degree of glycemic control over a period of ϳ2 weeks, as opposed to 2-3 months for gHb; and (b) neither test has been correlated with the development of long-term complications from diabetes mellitus, as was shown with gHb in the Diabetes Control and Complications Trial or with the United Kingdom Prospective Diabetes Study (1 ).
Laboratory Methods for Determining gHb
Boronate affinity or affinity-binding chromatography, cation-exchange chromatography, and immunoassays form the most common means for measuring gHb. Analysis of clinical laboratory proficiency surveys for gHb measurement, conducted by the College of American Pathologists in 1999, 2 revealed that more than one-half of participating clinical laboratories use boronate affinity chromatography for determining gHb, either as HbA 1c or as total gHb (14 ) . Approximately 30% use a cation-exchange or ion-exchange HPLC method. Nearly 15% use immunoassay methods, whereas Ͻ5% use electrophoretic methods. Common cation-exchange and HPLC systems include the Tosoh A1c 2.2ϩ and the Bio-Rad Variant, Diamat, and Diastat systems. Available immunoassays include the Bayer DCA-2000, a staple of gHb testing in physicians' offices, and the Roche TinaQuant II and Unimate assays. Boronate affinity chromatography and boronate affinitybinding methods include the Abbott IMx, the CLC 330 and CLC 385 from Primus Corporation, the Glyco-Tek from Helena Laboratories, and the Bio-Rad Variant GHB and Variant Express. The boronate affinity-binding methods measure total gHb but report results either as total gHb or as a corrected HbA 1c equivalent. 2 The College of American Pathologists 1999 data were used to calculate relative percentages of methods in use as this survey provides a more accurate indication of current trends. During the time of the 2000 GH2-A Survey Set, Abbott had withdrawn their reagents for the IMx from the market. Many laboratories using the IMx as their primary method thus switched to an alternative method for measuring gHb during this period, significantly affecting the ratios of methods in use.
Methods of gHb Determination and Mechanisms by Which Hb Variants and Derivatives May Affect Results cation-exchange chromatography
Cation-exchange chromatography separates Hb species based on charge differences. Hb species elute from the cation-exchange column at different times with the application of buffers of increasing ionic strength (13 ) (Fig. 1, C-E) ; variants known to produce these patterns are shown in Tables 1 and 2 and are discussed in the text. Interestingly, the same variant may produce falsely increased or decreased HbA 1c , depending on the method used. In individuals homozygous for variant Hbs, such as HbSS or HbCC, modifications to the HPLC protocol, the algorithms used to calculate Hb A 1c , and the use of altered reference ranges have been proposed to provide more accurate determinations of in vivo concentrations of HbX 1c (15 ) . However, clinicians should consider methods other than gHb for determining longterm glycemic control, given the multiple factors confounding the interpretation of gHb results for these individuals.
The native Hb variant co-elutes with HbA 1c (Fig. 1C (8 ) .
To confound matters, the co-elution of the variant Hb with HbA 1c or its separation from HbA 1c often depends on the method used. These inconsistencies arise from the distinct solvent mixture, column, and additional elution conditions, including temperature, pressure, flow rate, and program time, used in each system. The same Hb variant may thus yield very different results for HbA 1c , depending on the method used. Furthermore, the algorithms used to calculate HbA 1c can lead to inaccurate results if they do not recognize the presence of aberrant peaks and either provide warning flags or allow for corrections to make accurate determinations. (Fig. 1D ). This pattern overestimates the concentration of HbA 1c . The glycated Hb variant becomes incorporated in the HbA 1c peak, whereas the denominator consists only of the area under the native HbA peak. This effect occurs in the presence of Hb G Philadelphia on the Tosoh A1c 2.2ϩ system. Conversely, Hb G Philadelphia produces a falsely decreased (16, 17 ) . Other Hb variants with alterations in the first 4 -10 N-terminal amino acids could produce similar results. In the case of Hb Raleigh, the Val3 Ala substitution produces substantial acetylation at the NH 2 terminus, preventing the formation of the gHb at this position and further decreasing results obtained by immunoassay (16 ) . gHb determinations in this and other N-terminal variants, namely Hb Long Island (28 ), Hb South Florida (19 ) , and Hb Niigata (20 ) , are also of limited utility in assessing long-term diabetic control because of the extensive acetylation of Hb in vivo.
The glycated Hb variant co-elutes with HbA 1c , whereas the nonglycated Hb variant is resolved from HbA

boronate affinity chromatography
Among commercially available methods, boronate affinity chromatography tends to demonstrate the least interference from the presence of Hb variants and derivatives (5, 29, 30 ) . The method determines total gHb, including HbA 1c and ketoamine structures formed on lysines and N-terminal valine residues of both the ␣ and ␤ chains. m-Aminophenylboronic acid, cross-linked to agarose or glass beads, reacts specifically with cis-diol groups of glucose bound to Hb to form a reversible five-member ring complex, thus immobilizing gHb to the column. Addition of sorbitol dissociates the complex and elutes the gHb (13 ) . The gHb may then be measured spectrophotometrically or by quenching of Hb fluorescence with an added fluorophore.
Studies using the CLC 330 and CLC 385 (Primus Corporation) have reported no interference from common Hb variants or derivatives. Significant spurious increases in gHb values have been reported with the Quick Column method (Helena) in HbAC and HbCC samples (31 ) . One study reported a positive bias in gHb readings from HbAC samples with the Abbott IMx ® Glycated Hemoglobin assay, which uses a boronate/ion-capture method. Frank et al. (5 ) hypothesized that the bias may be attributable to the polyanion capture reagent, which may react with the Lys substitution at position 6 of nonglycated HbC.
Of the less common Hb variants that have been studied, only Hb Himeji (␤140Ala3 Asp) has demonstrated falsely increased gHb results, which were attributed to excessive glycation of Hb Himeji in vivo (32 ) . Accurate HbA 1c values were ultimately obtained by performing cation-exchange chromatography on the eluate with Iso Glyc-affin GHb columns. This fractionation allowed determination of HbA 1c relative to HbA ( Table 2 ). The authors hypothesized that the ␤140Ala3 Asp substitution in Hb Himeji may interact with the NH 2 terminus of the ␤ chain, enhancing the in vivo formation of Hb Himeji 1c (32 ) . (35 ) . The profile gives an accurate indication of total gHb as well as proportions of carbamylated and variant forms. In patients with Hb variants, the same profile can also provide information concerning the nature of the variants (35, 36 ) . Despite these attributes, the prohibitive cost of ES-MS and the complicated nature of its installation and operation make it unlikely that it will be used in most clinical laboratories in the near future (36 ) .
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Effect of Commonly Encountered Chemical Derivatives and Genetic Variants on gHb Methods
The findings of several studies concerning the effects of carbamyl-Hb, HbS, HbC, HbE, and HbF on common methods for determining gHb are summarized in Table 3 .
We have opted to present data from studies where (a) unless indicated, multiple samples with the given variant were studied, (b) measurements were performed on samples covering a range of expected gHb values, and (c) the comparison method is known to be unaffected by the variants under study.
carbamyl-Hb
Urea spontaneously dissociates in vivo to form ammonia and cyanate. Protonation of cyanate leads to the formation of isocyanic acid, which reacts with the ␣ and ⑀ amino groups on proteins, forming a carbamyl moiety (37 ) (38, 40 ) .
sickle trait
HbS (␤6Glu3 Val) is the most commonly encountered variant Hb in the United States; 7.8% of African Americans carry the sickle trait, whereas homozygous sickle cell disease afflicts nearly 50 000 Americans (41 ) . In parts of sub-Saharan Africa, the prevalence of HbAS has been shown to be as high as one-third of all patients undergoing HbA 1c testing (7 ) .
Commonly used boronate affinity methods have demonstrated accurate gHb readings in the presence of HbS (5, 15 ) . Effects of HbS on cation-exchange chromatographic assays vary, depending on the method and platform used. A recent study found overestimation of HbA 1c in the Bio-Rad Diamat or Variant HPLC systems, especially in the lower HbA 1c range. The interference from HbS varied in the Diamat system, depending on the lot of columns used (5 ) . Studies with the Tosoh gHb 2.2Acϩ and Menarini 8140 platforms showed no effect as HbS and HbS 1c were readily separable from HbA and HbA 1c (42, 43 ) . The epitopes recognized by the antibodies used in the DCA-2000 and TinaQuant fall within the first four and six amino acids and are not affected by the mutation in HbS (8, 27 ) . However, a significant spurious increase has been noted with the Roche Unimate immunoassay, which uses the same antibody as the Bayer DCA-2000 (44 ) . The Unimate assay differs from the DCA-2000 in that it uses pepsin to cleave the ␤ chain near the NH 2 terminus, and thus measures glycation on the peptide fragments. One study hypothesized that the antibody may have a higher affinity for the peptide fragments of HbS 1c and HbC 1c , leading to the spurious increases in gHb (44 ) .
HbC trait
HbC trait (␤6Glu3 Lys) has a prevalence of 2.3% among African Americans and a prevalence as high as 30% in parts of sub-Saharan Africa (41 ) . HbC trait behaves similarly to HbS trait with regard to many, but not all, assay systems. As discussed above, false increases have been reported with the boronate affinity/cation-capture method used in the Abbott IMx Glycated Hemoglobin method (5 ), with the Quick Column method from Helena Laboratories (31 ) and with the Roche Unimate immunoassay (44 ) . Use of the 3-min elution program on the Tosoh A1c 2.2ϩ has been recommended to fully separate HbC from HbA and allow for accurate readings (43, 45 ) 
HbCC and HbSC disease
Both HbCC and HbSC disease share the same confounding factors in the determination of gHb as HbSS disease, although both entities produce a less severe anemia than sickle cell disease. The prevalence of HbCC disease in the US is approximately 1 in 1800, whereas that of HbSC disease is 1 in 1100 (41 ) . Alternative forms of testing, as described above, should be considered for the determination of long-term glycemic control in these individuals.
HbF
At birth, HbF comprises 70% of all Hb, and falls to Ͻ5% by 6 months of age (47 ) . Individuals with hereditary persistence of HbF may have concentrations up to 30% of total Hb, whereas ␤-thalassemia and sickle cell patients commonly demonstrate concentrations ranging from 2% to 20% of total Hb (48 ) . Slight increases occur during pregnancy, with severe anemias, and in certain leukemias. Approximately 1.5% of the US population has HbF concentrations Ͼ2%, although the number of patients hospitalized in tertiary medical centers with HbF Ͼ2% has been found to be as high as 12% (49 ) . As indicated in Table 3 Although most modern chromatographic and immunoassay methods are either unaffected by common heterozygous variants such as HbAS, HbAC, and HbAE or give warning flags concerning the likelihood of an underlying variant, less common variants may give no such warnings. Furthermore, all gHb methods are inadequate for the assessment of long-term glycemic control in patients homozygous for HbS, HbC, or with HbSC disease. Although technologies such as boronate affinity chromatography and ES-MS provide a means of accurately determining gHb in these individuals, results are unlikely to accurately reflect long-term glycemic control due to pathological conditions that affect the formation and turnover of gHb in vivo.
In regions where populations have a high prevalence of variant Hbs, methods for the determination of gHb must be carefully selected to allow accurate determination of gHb in these individuals. When dealing with populations in which HbSS, HbCC, or HbSC disease are common and in which gHb determinations have limited utility, laboratories should offer alternative forms of testing, such Clinical Chemistry 47, No. 2, 2001 as GSPs or GSA, to assist physicians with the determination of glycemic control in these individuals.
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